DUB (uterine bleeding)

6,091 views
5,966 views

Published on

0 Comments
14 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
6,091
On SlideShare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1,636
Comments
0
Likes
14
Embeds 0
No embeds

No notes for slide

DUB (uterine bleeding)

  1. 1. ِAbnormal uterine bleeding Prof. Aboubakr Elnashar Benha University Hospital, Egypt E-mail: elnashar53@hotmail.com
  2. 2. DEFINE Any deviation in normal frequency, duration or amount of menstruation in women of reproductive age. NORMAL MENSES Frequency: 21-35 d Duration: 3-7 d Volume: 30-80 ml
  3. 3. CLINICAL TYPES Polymenorrhoea: frequent (<21 d) menstruation, at regular intervals Menorrhagia: Excessive (>80 ml) & / or prolonged menstruation, at regular intervals Metrorrhagia: Excessive (>80 ml) & / or prolonged menstruation at irregular intervals. Menometrorrhagia: both. Intermenstual bleeding: episodes of uterine bleeding between regular menstruations Hypomenorrhoea: scanty menstruation. Oligomenorrhoea: infrequent menstruation (>35 d)
  4. 4. <ul><li>CAUSES </li></ul><ul><ul><ul><li>. Dysfunctional uterine bleeding </li></ul></ul></ul><ul><ul><ul><li>. Pregnancy complications: </li></ul></ul></ul><ul><ul><ul><li>Abortion, Ectopic pregnancy, Trophoblastic disease </li></ul></ul></ul><ul><ul><ul><li>. Genital disease: </li></ul></ul></ul><ul><ul><ul><li>. Tumors: </li></ul></ul></ul><ul><ul><ul><li>Benign: fibroid, polyps (cervical, endometrial, fibroid) </li></ul></ul></ul><ul><li>Malignant: cervical, endometrial, ovarian (estrogen secreting) </li></ul><ul><ul><ul><li>. Infection: PID </li></ul></ul></ul><ul><ul><ul><li>. Endometriosis , adenomyosis </li></ul></ul></ul><ul><ul><ul><li>. IUCD </li></ul></ul></ul><ul><ul><ul><li>. Marked uterovaginal prolapse or retroversion </li></ul></ul></ul>
  5. 5. <ul><ul><ul><li>. Extragenital: </li></ul></ul></ul><ul><ul><ul><li>. Endocrine : hypo- or hyperthyroidism </li></ul></ul></ul><ul><ul><ul><li>. Haematological: Idiopathic thrombocytopenic purpura, Von-Willebrand disease </li></ul></ul></ul><ul><ul><ul><li>. Chronic systemic disease: liver failure, renal failure, hypertension with uterine artery atherosclerosis. </li></ul></ul></ul><ul><ul><ul><li>. Iatrogenic: Sex hormones, anticoagulants. </li></ul></ul></ul><ul><ul><ul><li>. Emotional: (change of country, climate & work; stress; psychosomatic disorders) </li></ul></ul></ul><ul><ul><ul><li>. Obesity: [increased peripheral estrogen conversion] </li></ul></ul></ul>
  6. 6. <ul><ul><ul><li>Dysfunctional uterine bleeding </li></ul></ul></ul><ul><li>Define </li></ul><ul><ul><li>Abnormal uterine bleeding in absence of pelvic organ disease or a systemic disorder </li></ul></ul><ul><ul><ul><li>Incidence </li></ul></ul></ul><ul><li>60 % of AUB </li></ul>
  7. 7. Pathology Endocrine abnormality Endometrium Anovulatory 90% Insufficient follicles Inadequate proliferative or atrophic Persistent follicles Proliferative or hyperplastic Ovulatory 10% Short proliferative phase Normal Long proliferative phase Normal Insufficient C. luteum Irregular or deficient secretory leading to short luteal phase Persistent C luteum leading to Irregular shedding long luteal phase
  8. 9. <ul><li>Risk of endometrial cancer </li></ul><ul><li>Chronic anovulation has 3 times increased risk (Coulam,1989). Chronic proliferation of the endometrium leading to adenomatous hyperplasia, leading to atypical adenomatous hyperplasia, leading to endometrial carcinoma. Transition can take up to 10 yrs or more. </li></ul>
  9. 10. <ul><ul><ul><li>Diagnosis </li></ul></ul></ul><ul><li>Aim: </li></ul><ul><li>1. Nature & severity of bleeding </li></ul><ul><li>2. Exclusion of organic causes </li></ul><ul><li>3. Ovulatory or anovulatory </li></ul><ul><li>How: </li></ul>
  10. 11. I. History: 1. Personal: age, wishes of the patient 2. Menstrual 3. Obstetric 4. Past 5. Present: amount, duration, color, smell, relation to sexual intercourse, associated symptoms
  11. 12. II. Examination: 1. General: pallor, endocrinopathy, coagulopathy, pregnancy 2. Abdominal: liver, spleen, pelvic abdominal mass 3. Pelvic: origin of the bleeding, cause
  12. 13. <ul><ul><ul><ul><ul><li>III.Investigations </li></ul></ul></ul></ul></ul><ul><li>Systemic: </li></ul><ul><li>1. CBC (for all, Grade A) </li></ul><ul><li>2. BHCG </li></ul><ul><li>3. Prolactin & TSH </li></ul><ul><li>4. Prothrombin time, partial thromboplastin time, bleeding time, platelets, Von Willebrand factor </li></ul>
  13. 14. Local: 1. Pap smear 2. Endometrial biopsy 3. D & C 4. Hysteroscopy 5. U/S
  14. 16. Assessment of the amount of the bleeding: 50% of excessive menstruation have normal amount of blood loss by objective methods 1.Subjective methods: history of passage of clots, flooding, use of large number of pads, do not reflect the actual blood loss 2.Semiobjective: i.Iron deficiency anemia ii.Menstrual calendar (August,1996) III. Pictorial blood loss chart (Higham,1990) :
  15. 17. Menstrual calender (August,1996) Saturday 7 14 21 28 Sunday 1 8 15 22 29 Monday 2 9 16 23 30 Tuesday 3 10 17 24 31 Wednesday 4 11 18 25 Thursday 5 12 19 26 Friday 6 13 20 27 . Spotting - Slight loss O Moderate loss Very heavy loss
  16. 18. Pictorial blood loss chart: (Higham,1990) Days of the bleeding Score 1 2 3 4 5 6 7 8 Towel 1 point 5 points 10 points Clots 1p clot 1 point 5p clot 5 points Flooding 5 points Score >100 = Menorrrhagia
  17. 19. Endometrial biopsy: Indications: .Between 20 & 40 .If endometrial thickness on TVS is >12mm, endometrial sample should be taken to exclude endometrial hyperplasia (Grade A). Failure to obtain sufficient sample for H/P does not require further investigation unless the endometrial thickness is >12 mm (Grade B) Aim: diagnosis of the type of the bleeding
  18. 20. Methods: As an outpatient procedure, without general anesthesia. 1.Pipelle curette 2.Sharman curette, Gravlee jet washer, Isac cell sampler 3.Accrette 4.vabra aspirator Advantages: An adequate & acceptable screening procedure in females under 40 yrs
  19. 22. D & C: Indications: 1. Mandatory after 40 yrs 2. Persistent or recurrent bleeding between 20 & 40 yrs Aim: 1.Diagnosis of organic disease e.g. endometritis, polyp, carcinoma, TB, fibroid 2.Diagnosis of the type of the endometrium: hyperplastic, proliferative, secretory, irregular ripening, shedding, atrophic. This provides a guide to etiology & treatment
  20. 23. 3.Arrest of the bleeding, if the bleeding is severe or persistent, particularly hyperplastic endometrium. Curettage is essentially a diagnostic & not a therapeutic procedure. Disadvantages: 1.Small lesions can be missed 2.The sensitivity of detecting intrauterine pathology is only 65%
  21. 24. Fractional curretage: Indication: >40 yrs Method: 3 samples: endocervical, lower segment & upper segment
  22. 25. Hysteroscopy: Indications: Mandatory after 40 yrs 1. Erratic menstrual bleeding 2. Failed medical treatment 3. TVS suggestive of intrauterine pathology e.g. polyp, fibroid (Grade B)
  23. 26. Aim: 1.Excellent view of the uterine cavity & diagnosis of polyps, submucous fibroid, hyperplasia. 2.Biopsy of the suspected areas 3.Treatment
  24. 27. Advantages over D &C 1.The whole uterine cavity can be visualized 2.Very small lesions such as polyps can be identified & biopsed or removed 3.Bleeding from ruptured venules & echymoses can be readily identified 4.The sensitivity in detecting intrauterine pathology is 98% (Loffer,1989) 5.Outpatient procedure
  25. 28. Disadvantages: 1.Cost of the apparatus 2.Lack of availability or experience
  26. 29. Ultrasonography: 1. TAS: can exclude pelvic masses, pregnancy complications 2. TVS: More informative than TAS. Measurement of the endometrial thickness is not a replacement for biopsy. All endometrial carcinoma in postmenopausal with endometrial thickness>4 mm (Osmers,1990) 3. Saline sonography: an alternative to office hysteroscopy in selected cases. It is better tolerated than office hysteroscopy or HSG
  27. 30. TVS is recommended in: 1. Weight >90 Kg 2. Age > 40 yrs 3. Other risk factors for endometrial hyperplasia or carcinoma e.g. infertility, nulliparity, family history of colon or endometrial cancer, exposure to unopposed estrogen (Grade B)
  28. 31. <ul><ul><ul><li>Treatment </li></ul></ul></ul><ul><ul><ul><li>A. General </li></ul></ul></ul><ul><li>1. Menstrual calendar </li></ul><ul><li>2. Treatment of iron deficiency anemia </li></ul>
  29. 32. <ul><ul><ul><ul><ul><li>B. Medical </li></ul></ul></ul></ul></ul><ul><li>I. Hormonal: </li></ul><ul><li>1.Progestagen </li></ul><ul><li>2.Oestrogen </li></ul><ul><li>3.COCP </li></ul><ul><li>4.Danazol </li></ul><ul><li>5.GnRh agonist </li></ul><ul><li>6.Levo-nova (Merina) </li></ul><ul><li>II. Non –hormonal </li></ul><ul><li>1.Prostaglandin synthetase inhibitors (PSI) </li></ul><ul><li>2.Antifibrinolytics </li></ul><ul><li>3.Ethamsylate </li></ul>
  30. 33. <ul><ul><ul><ul><ul><li>C. Surgical </li></ul></ul></ul></ul></ul><ul><li>1. Endometrial ablation </li></ul><ul><li>2. Hysterectomy </li></ul>
  31. 34. Strategy of treatment <20 yrs 20-40 yrs > 40 yrs Medical Always First resort after endometrial biopsy Temporizing & if surgery is refused or imminent menopause Surgical Never Seldom, only if medical treatment fail First resort if bleeding is recurrent
  32. 35. Medical treatment: Antifibrinolytics Mechanism of action: The endometrium possess an active fibrinolytic system, & the fibrinolytic activity is higher in menorrhagia. Effect: Greater reduction of menstrual bleeding than other therapies (PSI, oral luteal phase progestagen & etamsylate)(Cochrane library,2002). Tranexamic acid is effective in treating menorrhagia associated with IUCD.
  33. 36. Side effects: is dose related. Nausea , vomiting, diarrhea, dizziness. Rarely: transient color vision disturbance, intracranial thrombosis. But, no evidence that tranxemic acid increases the risk in absence of past or family history of thrombophilia. This treatment is not associated with an increase in side effects compared to placebo or other therapies (Cochrane library,2002). Dose: 3-6 gm /d for the first 3 days of the cycle
  34. 37. PSI: Mechanism; the endometrium is a rich source of PGE 2 & PGF 2 œ & its concentrations are greater in menorrhagia. PSI decreases endometrial PG concentrations. Effect: PSI decreased menstrual blood by 24% & norethisterone by 20%. The beneficial effect of mefenamic acid on MBL & other symptoms e.g. dysmenorrhea, headache, nausea, diarrhea & depression persists for several months.
  35. 38. Dose: Mefenamic acid 500 mg tds during menses. Side effects: nausea, vomiting, gastric discomfort, diarrhea, dizziness. Rarely: haemolytic anemia, thrombocytopenia. The degree of reduction of MBL is not as great as it is with tranxamic acid but PSI have a lower side effect profile.
  36. 39. <ul><ul><li>Etamsylate: </li></ul></ul><ul><ul><li>Mechanism of action: </li></ul></ul><ul><ul><li>maintain capillary integrity, anti-hyalurunidase activity & inhibitory effect on PG </li></ul></ul><ul><ul><li>Dose: </li></ul></ul><ul><ul><li>500 mg qid, starting 5 days before anticipated onset of the cycle & continued for 10 days </li></ul></ul>
  37. 40. <ul><ul><li>Effect: </li></ul></ul><ul><ul><li>20% reduction in MBL. </li></ul></ul><ul><ul><li>There is no conclusive evidence of the effectivness of etamsylate in reducing menorrhgea (Grade A) </li></ul></ul><ul><ul><li>Side effects: </li></ul></ul><ul><ul><li>headache, rash, nausea </li></ul></ul>
  38. 41. Systemic progestagens: Norethisterone & medroxyprogesterone acetate Effect: Ovulatory DUB: not effective if given at low dose for short duration (5-10 days) in the luteal phase. Effective if NEA is given at higher dose for 3 w out of 4 w (5 mg tds from D5 to 26) Anovulatory DUB: useful Side effects: weight gain, nausea, bloating, edema, headache, acne, depression, exacerbation of epilepsy & migraine, loss of libido
  39. 42. <ul><ul><li>Intrauterine progestagens </li></ul></ul><ul><li>Levonorgestrel intrauterine system levonova,Mirena: Delivers 20ug LNG /d. for 5 yr </li></ul><ul><li>Metraplant: T shaped IUCD & levonorgestrel on the shoulder & stem </li></ul><ul><li>Azzam IUCD: Cu T & levonorgestrel on the stem </li></ul>
  40. 43. <ul><ul><li>Effect; </li></ul></ul><ul><ul><li>1. Comparable to endometrial resection for management of DUB. </li></ul></ul><ul><ul><li>2. Superior to PSI & antifibrinolytics </li></ul></ul><ul><ul><li>3.May be an alternative to hysterectomy in some patients </li></ul></ul>
  41. 45. <ul><ul><li>Side effects; </li></ul></ul><ul><ul><li>1.BTB in the first cycles </li></ul></ul><ul><ul><li>2.20% develop amenorrhea within 1 yr </li></ul></ul><ul><ul><li>3.Functional ovarian cysts </li></ul></ul><ul><ul><li>Special indications: </li></ul></ul><ul><ul><li>1. Intractable bleeding associated with chronic illness </li></ul></ul><ul><ul><li>2. Ovulatory heavy bleeding </li></ul></ul>
  42. 46. The combined contraceptive pill: Effect: Reduce MBL by 50% Mechanism of action: endometrial suppression Side effects; headache, migraine, weight gain, breast tenderness, nausea, cholestatic jaundice, hypertension, thrombotic episodes,
  43. 47. Danazol: synthetic androgen with antioestrogenic & antiprogestagenic activity Mechanism; inhibits the release of pituitary Gnt & has direct suppressive effect on the endometrium Effect: reduction in MBL (more effective than PSI) & amenorhea at doses >400 mg/d
  44. 48. Side effects: headache, weight gain, acne, rashes, hirsuitism, mood & voice changes, flushes, muscle spasm, reduced HDL, diminished breast size. Rarely: cholestatic jaundice. It is effective in reducing blood loss but side effects limit it to a second choice therapy or short term use only (Grade A) Dose: 200 mg/d
  45. 49. <ul><ul><li>GnRH analog </li></ul></ul><ul><ul><li>Side effects; </li></ul></ul><ul><ul><li>hot flushes, sweats, headache, irritability, loss of libido, vaginal dryness, lethargy, reduced bone density. </li></ul></ul>
  46. 50. <ul><ul><li>Surgical treatment </li></ul></ul><ul><ul><li>Endometrial ablation </li></ul></ul><ul><ul><li>Methods: </li></ul></ul><ul><ul><li>I. Hysteroscopic: </li></ul></ul><ul><ul><li>1. Laser </li></ul></ul><ul><ul><li>2. Electrosurgical: a. Roller ball </li></ul></ul><ul><ul><li>b. Resection </li></ul></ul><ul><ul><li>II. Non-hysteroscopic: </li></ul></ul><ul><ul><li>1. Thermachoice </li></ul></ul><ul><ul><li>2. Microwave. </li></ul></ul>
  47. 54. <ul><ul><li>Indications: </li></ul></ul><ul><ul><li>1. Failure of medical treatment </li></ul></ul><ul><ul><li>2. Family is completed </li></ul></ul><ul><ul><li>3. Uterine cavity <10 cm </li></ul></ul><ul><ul><li>4. Submucos fibroid <5 cm </li></ul></ul><ul><ul><li>5. Endometrium is normal or low risk hyperplasia. </li></ul></ul>
  48. 55. <ul><ul><li>Complications of hysteroscopic methods </li></ul></ul><ul><ul><li>1. Uterine perforation </li></ul></ul><ul><ul><li>2. Bleeding </li></ul></ul><ul><ul><li>3. Infection. </li></ul></ul><ul><ul><li>4. Fluid overload </li></ul></ul><ul><ul><li>5. Gas embolism </li></ul></ul>
  49. 56. <ul><ul><li>Hysterectomy </li></ul></ul><ul><li>Indications: </li></ul><ul><ul><li>1. Failure of medical treatment </li></ul></ul><ul><ul><li>2. Family is completed </li></ul></ul><ul><li>Routes: </li></ul><ul><li>1. Abdominal </li></ul><ul><li>2. Vaginal </li></ul><ul><li>3. Laparoscopic </li></ul>
  50. 57. Advantages: 1. Complete cure 2. Avoidance of long term medical treatment 3. Removal of any missed pathology Disadvantages: 1.Major operation 2.Hospital admission 3.Mortality & morbidity
  51. 58. Thank you Prof Aboubakr Elnashar Benha University Hospital E-mail:elnashar53@hotmail.com

×